ZA974576B - Pharmaceutical composition. - Google Patents

Pharmaceutical composition.

Info

Publication number: ZA974576B
Authority: ZA; South Africa
Prior art keywords: compounds; mesembrine; disclosed; pharmaceutical composition; mesembranol
Prior art date: 1996-06-04

Application number

ZA9704576A

Other languages

English (en)

Inventor

Nigel Peter Gericke

Ben-Erik Van Wyk

Original Assignee

Farmarc Nederland Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-04

Filing date

1997-05-26

Publication date

1998-02-04

1997-05-26 Application filed by Farmarc Nederland Bv filed Critical Farmarc Nederland Bv

1997-05-26 Priority to ZA9704576A priority Critical patent/ZA974576B/xx

1998-02-04 Publication of ZA974576B publication Critical patent/ZA974576B/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
DAHIQPJTGIHDGO-IRXDYDNUSA-N Mesembrine Chemical compound C1=C(OC)C(OC)=CC=C1[C@@]1(CCC(=O)C2)[C@H]2N(C)CC1 DAHIQPJTGIHDGO-IRXDYDNUSA-N 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
KPMLOZVRLWHOBN-UHFFFAOYSA-N 3a-(3,4-dimethoxyphenyl)-1-methyl-3,4,5,6,7,7a-hexahydro-2h-indol-6-ol Chemical compound C1=C(OC)C(OC)=CC=C1C1(CCC(O)C2)C2N(C)CC1 KPMLOZVRLWHOBN-UHFFFAOYSA-N 0.000 abstract 2
208000020016 psychiatric disease Diseases 0.000 abstract 2
241000219479 Aizoaceae Species 0.000 abstract 1
208000007848 Alcoholism Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010006550 Bulimia nervosa Diseases 0.000 abstract 1
208000020401 Depressive disease Diseases 0.000 abstract 1
241000196324 Embryophyta Species 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
241001601435 Mesembryanthemum sect. Planifolia Species 0.000 abstract 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
201000007930 alcohol dependence Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
206010013663 drug dependence Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
DAHIQPJTGIHDGO-UHFFFAOYSA-N mesembrine Natural products C1=C(OC)C(OC)=CC=C1C1(CCC(=O)C2)C2N(C)CC1 DAHIQPJTGIHDGO-UHFFFAOYSA-N 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

ZA9704576A 1996-06-04 1997-05-26 Pharmaceutical composition. ZA974576B (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
ZA9704576A ZA974576B (en)	1996-06-04	1997-05-26	Pharmaceutical composition.

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ZA964595		1996-06-04
ZA9704576A ZA974576B (en)	1996-06-04	1997-05-26	Pharmaceutical composition.

Publications (1)

Publication Number	Publication Date
ZA974576B true ZA974576B (en)	1998-02-04

Family

ID=25585724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9704576A ZA974576B (en)	1996-06-04	1997-05-26	Pharmaceutical composition.

Country Status (9)

Country	Link
US (1)	US6288104B1 (de)
EP (1)	EP0910372B1 (de)
JP (2)	JP4315469B2 (de)
CN (1)	CN1227487A (de)
AT (1)	ATE248593T1 (de)
AU (1)	AU716611B2 (de)
DE (1)	DE69724618T2 (de)
WO (1)	WO1997046234A1 (de)
ZA (1)	ZA974576B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7643874B2 (en)	2001-10-24	2010-01-05	Power Paper Ltd.	Dermal patch
JP4394444B2 (ja)	2001-10-24	2010-01-06	パワーペーパーリミティド	活性物質の制御された皮膚内デリバリーのためのデバイス及び方法
AU2002347567B2 (en)	2001-10-24	2008-07-17	Power Paper Ltd.	Dermal patch
US7785324B2 (en)	2005-02-25	2010-08-31	Endoscopic Technologies, Inc. (Estech)	Clamp based lesion formation apparatus and methods configured to protect non-target tissue
WO2005051381A1 (en) *	2003-11-26	2005-06-09	Biovitrum Ab	Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)
WO2005051380A1 (en) *	2003-11-26	2005-06-09	Biovitrum Ab	Substituted urea-octahydroindols as antagonists of melanin concentrating hormone receptor 1 (mch1r)
TW200640529A (en) *	2005-02-28	2006-12-01	Thomas Christian Lines	Composition for treating mental health disorders
US20070149600A1 (en) *	2005-04-25	2007-06-28	Andrew Browning	Substituted octahydroisoindoles
WO2010106494A1 (en) *	2009-03-20	2010-09-23	H.L. Hall & Sons Limited	Use of pharmaceutical compositions containing mesembrenone
AU2010224486B2 (en) *	2009-03-20	2014-04-24	Hg&H Pharmaceuticals (Pty) Ltd	Sceletium extract and uses thereof
WO2011092547A1 (en)	2010-01-29	2011-08-04	Council Of Scientific & Industrial Research	Triazine-aryl-bis-indoles and process for preparation thereof
US9752932B2 (en)	2010-03-10	2017-09-05	Drexel University	Tunable electro-optic filter stack
US9576694B2 (en)	2010-09-17	2017-02-21	Drexel University	Applications for alliform carbon
US20160038551A1 (en)	2013-03-28	2016-02-11	Botanical Resource Holdings Proprietary Limited	Stabilized mesembrine compositions
WO2015130994A1 (en)	2014-02-28	2015-09-03	Tripp Matthew L	Phosphodiesterase-4 inhibiting phytochemical compositions
US20220031660A1 (en) *	2015-03-27	2022-02-03	Botanical Resource Holdings (Proprietary) Limited	Cancer treatment composition
WO2016157045A1 (en) *	2015-03-27	2016-10-06	Botanical Resource Holdings (Proprietary) Limited	Cancer treatment composition
CN106866496B (zh) *	2017-04-21	2019-10-15	中国科学院上海有机化学研究所	六氢苯并喹啉-6-酮和六氢苯并吲哚-5-酮化合物、合成方法及用途
EP3658167A1 (de) *	2017-07-26	2020-06-03	HG&H Pharmaceuticals (Pty) Limited	Mesembrenol und / oder mesembranol zur prophylaxe und behandlung von patienten mit epilepsie und assoziierten krankheiten
CA3202844A1 (en) *	2020-12-21	2022-06-30	Ryan PROTZKO	Methods for delay of ejaculation in human males
CN113072576B (zh) *	2021-04-07	2022-04-26	四川大学	一类手性硅代松叶菊碱、合成方法及用途
EP4373575A1 (de) *	2021-07-22	2024-05-29	Kanna Health Ltd.	Neue verbindungen und ihre verwendungen
CA3233930A1 (en) *	2021-10-19	2023-04-27	Justin KIRKLAND	Mesembrine derivatives
US20250051277A1 (en)	2021-10-29	2025-02-13	Sensorium Therapeutics, Inc.	Delivery of therapeutic alkaloid compounds
WO2023076533A1 (en) *	2021-10-29	2023-05-04	Sensorium Therapeutics, Inc.	Solid forms of mesembrine and therapeutic uses thereof
WO2023166304A1 (en) *	2022-03-02	2023-09-07	Kanna Health Ltd	Compounds for the use in the treatment of mood disorders
GB2616343A (en) *	2022-03-02	2023-09-06	Kanna Health Ltd	Compounds for the use in the treatment of mood disorders
GB2619907A (en)	2022-04-01	2023-12-27	Kanna Health Ltd	Novel crystalline salt forms of mesembrine
US12410128B1 (en)	2022-04-15	2025-09-09	Sensorium Therapeutics, Inc.	Therapeutic alkaloid compounds
WO2023225773A1 (en) *	2022-05-23	2023-11-30	Sensorium Therapeutics, Inc.	Solid forms of mesembrine and therapeutic uses thereof
WO2024015559A2 (en) *	2022-07-15	2024-01-18	Sensorium Therapeutics, Inc.	Solid forms of mesembrine and therapeutic uses thereof
GB2623122A (en) *	2022-10-07	2024-04-10	Kanna Health Ltd	Preparation of mesembrine
WO2024102991A1 (en) *	2022-11-11	2024-05-16	Sensorium Therapeutics, Inc.	Therapeutic alkaloid compounds
WO2024102461A1 (en) *	2022-11-11	2024-05-16	Sensorium Therapeutics, Inc.	Alkyl-substituted derivatives of mesembrine and mesembrenone and therapeutic uses thereof
AU2023413043A1 (en) *	2022-12-22	2025-07-03	Sensorium Therapeutics, Inc.	Delivery of therapeutic alkaloid compounds
WO2024173800A2 (en) *	2023-02-17	2024-08-22	Sensorium Therapeutics, Inc.	Solid forms of mesembranol and therapeutic uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3604112A1 (de)	1986-02-10	1987-08-13	Bernhard Dr Janiak	Pflanzenextrakte von mesembryanthemaceen sowie solche enthaltende schaedlingsbekaempfungsmittel und arzneimittel

1997
- 1997-05-26 ZA ZA9704576A patent/ZA974576B/xx unknown
- 1997-06-03 EP EP97924158A patent/EP0910372B1/de not_active Expired - Lifetime
- 1997-06-03 WO PCT/GB1997/001493 patent/WO1997046234A1/en not_active Ceased
- 1997-06-03 DE DE69724618T patent/DE69724618T2/de not_active Expired - Lifetime
- 1997-06-03 AU AU29722/97A patent/AU716611B2/en not_active Expired
- 1997-06-03 CN CN97197056A patent/CN1227487A/zh active Pending
- 1997-06-03 US US09/194,836 patent/US6288104B1/en not_active Expired - Lifetime
- 1997-06-03 JP JP50031498A patent/JP4315469B2/ja not_active Expired - Fee Related
- 1997-06-03 AT AT97924158T patent/ATE248593T1/de not_active IP Right Cessation
2008
- 2008-10-22 JP JP2008272215A patent/JP2009062387A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP0910372B1 (de)	2003-09-03
JP2000511896A (ja)	2000-09-12
DE69724618D1 (de)	2003-10-09
US6288104B1 (en)	2001-09-11
AU2972297A (en)	1998-01-05
DE69724618T2 (de)	2005-04-21
AU716611B2 (en)	2000-03-02
JP2009062387A (ja)	2009-03-26
ATE248593T1 (de)	2003-09-15
CN1227487A (zh)	1999-09-01
EP0910372A1 (de)	1999-04-28
WO1997046234A1 (en)	1997-12-11
JP4315469B2 (ja)	2009-08-19

Publication	Publication Date	Title
AU2972297A (en)	1998-01-05	Pharmaceutical compositions containing mesembrine and related compounds
MX9702865A (es)	1998-05-31	Agentes estrogenicos.
MY115339A (en)	2003-05-31	Compositions containing micronized nebivolol
GEP20063885B (en)	2006-08-10	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
UA66861C2 (uk)	2004-06-15	2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
DE69427704D1 (de)	2001-08-16	Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
FR2764887B1 (fr)	2004-04-02	Melange de diphenylamines nonylees, procede pour le preparer et composition le contenant
AR002705A1 (es)	1998-04-29	Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
IL85022A0 (en)	1988-06-30	Pyrazoline derivatives and their use as insecticides
IL125282A (en)	2003-06-24	Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
BG105481A (en)	2001-12-29	Tricyclic pyrazole derivatives
DK0695758T3 (da)	2002-08-19	Pentapeptidamider og -estere til inhibering af human cancer
IL138476A0 (en)	2001-10-31	Method for treating pharmaceutical compositions by special use of anti-oxidant
ZA948669B (en)	1995-07-04	New pyrazine carboxamide derivatives the preparation thereof and their use in pharmaceutical compositions
DK0564350T3 (da)	1997-12-15	3, 5-di-tert-butyl-4-hydroxyflavoner, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger med antioxidant- og anti-vasokonstriktorisk virkning
ATE159250T1 (de)	1997-11-15	Neue pyrazinderivative, ihre herstellung und verwendung
SE8703169D0 (sv)	1987-08-14	1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h-2,3-benzodiazepine, acid addition salts thereof and process for preparing same
HUP9901326A3 (en)	2000-12-28	Benzopyran derivatives having leukotriene-antagonistic action, pharmaceutical compositions containing these compounds, process for the preparation and use of these compounds and compositions
ATE348812T1 (de)	2007-01-15	Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
IL126235A (en)	2003-02-12	Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ATE290857T1 (de)	2005-04-15	Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
MX9704034A (es)	1998-02-28	Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
MY107354A (en)	1995-11-30	Substituted cyclohexenes as central nervous system agents
DE69519203D1 (de)	2000-11-30	Verfahren zur Herstellung von Extrakten enthaltende polyphenalische oligomere Verbindungen von Catechin-Typ, aus pflanzenartigen Quellen, und diese erhaltene Extrakte
UA48962C2 (uk)	2002-09-16	Біциклічні антагоністи тахікінінів, фармацевтична композиція та спосіб лікування